182 related articles for article (PubMed ID: 24094723)
21. [Risk profiles for suicide of schizophrenic and depressive inpatients - a psychological autopsy study].
Neuner T; Mehlsteibl D; Hübner-Liebermann B; Schmid R; Schielein T; Hausner H; Hajak G; Spiessl H
Psychiatr Prax; 2010 Apr; 37(3):119-26. PubMed ID: 19823967
[TBL] [Abstract][Full Text] [Related]
22. Early non-adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder.
Bodén R; Brandt L; Kieler H; Andersen M; Reutfors J
Schizophr Res; 2011 Dec; 133(1-3):36-41. PubMed ID: 21982098
[TBL] [Abstract][Full Text] [Related]
23. A prospective study on the pattern of medication use for schizophrenia in the outpatient pharmacy department, Hospital Tengku Ampuan Rahimah, Selangor, Malaysia.
Ponto T; Ismail NI; Abdul Majeed AB; Marmaya NH; Zakaria ZA
Methods Find Exp Clin Pharmacol; 2010; 32(6):427-32. PubMed ID: 20852752
[TBL] [Abstract][Full Text] [Related]
24. Somnolence effects of antipsychotic medications and the risk of unintentional injury.
Said Q; Gutterman EM; Kim MS; Firth SD; Whitehead R; Brixner D
Pharmacoepidemiol Drug Saf; 2008 Apr; 17(4):354-64. PubMed ID: 18314925
[TBL] [Abstract][Full Text] [Related]
25. Treatment adherence and insight in schizophrenia.
Bitter I; Fehér L; Tényi T; Czobor P
Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
[TBL] [Abstract][Full Text] [Related]
26. [Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone].
Bret P; Bonnet F; Bret MC; Jaffré A
Encephale; 2002; 28(4):329-42. PubMed ID: 12232542
[TBL] [Abstract][Full Text] [Related]
27. Use and safety of antipsychotic drugs during pregnancy.
Einarson A; Boskovic R
J Psychiatr Pract; 2009 May; 15(3):183-92. PubMed ID: 19461391
[TBL] [Abstract][Full Text] [Related]
28. Antidepressant drug therapy and suicide in severely depressed children and adults: A case-control study.
Olfson M; Marcus SC; Shaffer D
Arch Gen Psychiatry; 2006 Aug; 63(8):865-72. PubMed ID: 16894062
[TBL] [Abstract][Full Text] [Related]
29. Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia.
Lambert BL; Chang KY; Tafesse E; Carson W
J Clin Psychopharmacol; 2005 Feb; 25(1):12-8. PubMed ID: 15643095
[TBL] [Abstract][Full Text] [Related]
30. Excessive dosing and polypharmacy of antipsychotics caused by pro re nata in agitated patients with schizophrenia.
Fujita J; Nishida A; Sakata M; Noda T; Ito H
Psychiatry Clin Neurosci; 2013 Jul; 67(5):345-51. PubMed ID: 23711166
[TBL] [Abstract][Full Text] [Related]
31. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia.
Lewis SW; Barnes TR; Davies L; Murray RM; Dunn G; Hayhurst KP; Markwick A; Lloyd H; Jones PB
Schizophr Bull; 2006 Oct; 32(4):715-23. PubMed ID: 16540702
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study.
Tiihonen J; Wahlbeck K; Lönnqvist J; Klaukka T; Ioannidis JP; Volavka J; Haukka J
BMJ; 2006 Jul; 333(7561):224. PubMed ID: 16825203
[TBL] [Abstract][Full Text] [Related]
33. Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine.
Werneck AP; Hallak JC; Nakano E; Elkis H
Psychiatry Res; 2011 Aug; 188(3):315-9. PubMed ID: 21596442
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Rosenheck RA; Leslie DL; Sindelar J; Miller EA; Lin H; Stroup TS; McEvoy J; Davis SM; Keefe RS; Swartz M; Perkins DO; Hsiao JK; Lieberman J;
Am J Psychiatry; 2006 Dec; 163(12):2080-9. PubMed ID: 17151158
[TBL] [Abstract][Full Text] [Related]
35. Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.
Citrome L; Kalsekar I; Guo Z; Laubmeier K; Hebden T
Clin Ther; 2013 Dec; 35(12):1867-75. PubMed ID: 24119767
[TBL] [Abstract][Full Text] [Related]
36. Altered metabolic parameters in association with antipsychotic medication use in diabetes: A population based case-control study.
Wake DJ; Broughton P; Perera SM; MacIntyre DJ; Leese GP
Psychoneuroendocrinology; 2016 Apr; 66():214-20. PubMed ID: 26849203
[TBL] [Abstract][Full Text] [Related]
37. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
38. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
[TBL] [Abstract][Full Text] [Related]
39. Choosing antipsychotic maintenance therapy--a naturalistic study.
Tavcar R; Dernovsek MZ; Zvan V
Pharmacopsychiatry; 2000 Mar; 33(2):66-71. PubMed ID: 10761822
[TBL] [Abstract][Full Text] [Related]
40. [Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: Patient characteristics, antipsychotic treatment, and care management for schizophrenia].
Brunot A; Lachaux B; Sontag H; Casadebaig F; Philippe A; Rouillon F; Cléry-Melin P; Hergueta T; Llorca PM; Moreaudefarges T; Guillon P; Lebrun T
Encephale; 2002; 28(2):129-38. PubMed ID: 11972139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
